Comparison of pharmacokinetics between loxoprofen and its derivative with lower ulcerogenic activity, fluoro-loxoprofen

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2013, Pages 118-124

  Yamakawa, Naoki ^a,b   Suemasu, Shintaro ^a,b   Watanabe, Hiroshi ^b   Tahara, Kayoko ^a   Tanaka, Ken ichiro ^b   Okamoto, Yoshinari ^b   Ohtsuka, Masami ^b   Maruyama, Toru ^b   Mizushima, Tohru ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Gastric lesions; Liver homogenates; Loxoprofen; Pharmacokinetics; Rat

Indexed keywords

FLUOROLOXOPROFEN; LOXOPROFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; NONHUMAN; RAT; ULCEROGENICITY;

EID: 84876768292     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-050     Document Type: Article

References (34)

1. Smalley, W. E., Ray, W. A., Daugherty, J. R. and Griffin, M. R.: Nonsteroidal anti-inflammatory drugs and the incidence of hospital-izations for peptic ulcer disease in elderly persons. Am. J. Epidemiol., 141: 539-545 (1995).
2. Hawkey, C. J.: Nonsteroidal anti-inflammatory drug gastropathy. Gastro-enterology, 119: 521-535 (2000).
3. Barrier, C. H. and Hirschowitz, B. I.: Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum., 32: 926-932 (1989).
4. Fries, J. F., Miller, S. R., Spitz, P. W., Williams, C. A., Hubert, H. B. and Bloch, D. A.: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology, 96: 647-655 (1989).
5. Ligumsky, M., Golanska, E. M., Hansen, D. G. and Kauffman, G. J.: Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology, 84: 756-761 (1983).
6. Ligumsky, M., Sestieri, M., Karmeli, F., Zimmerman, J., Okon, E. and Rachmilewitz, D.: Rectal administration of nonsteroidal antiinflammatory drugs. Effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis. Gastroenterology, 98: 1245-1249 (1990).
7. Tanaka, K., Tomisato, W., Hoshino, T., Ishihara, T., Namba, T., Aburaya, M., Katsu, T., Suzuki, K., Tsutsumi, S. and Mizushima, T.: Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J. Biol. Chem., 280: 31059-31067 (2005).
8. Tsutsumi, S., Gotoh, T., Tomisato, W., Mima, S., Hoshino, T., Hwang, H. J., Takenaka, H., Tsuchiya, T., Mori, M. and Mizushima, T.: Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ., 11: 1009-1016 (2004).
9. Tomisato, W., Tanaka, K., Katsu, T., Kakuta, H., Sasaki, K., Tsutsumi, S., Hoshino, T., Aburaya, M., Li, D., Tsuchiya, T., Suzuki, K., Yokomizo, K. and Mizushima, T.: Membrane permeabilization by non-steroidal anti-inflammatory drugs. Biochem. Biophys. Res. Commun., 323: 1032-1039 (2004).
10. Tomisato, W., Tsutsumi, S., Rokutan, K., Tsuchiya, T. and Mizushima, T.: NSAIDs induce both necrosis and apoptosis in guinea pig gastric mucosal cells in primary culture. Am. J. Physiol. Gastrointest. Liver Physiol., 281: G1092-G1100 (2001).
11. Aburaya, M., Tanaka, K., Hoshino, T., Tsutsumi, S., Suzuki, K., Makise, M., Akagi, R. and Mizushima, T.: Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. J. Biol. Chem., 281: 33422-33432 (2006).
12. Tsutsumi, S., Namba, T., Tanaka, K. I., Arai, Y., Ishihara, T., Aburaya, M., Mima, S., Hoshino, T. and Mizushima, T.: Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apop-tosis in human gastric cells. Oncogene, 25: 1018-1029 (2006).
13. Namba, T., Hoshino, T., Tanaka, K., Tsutsumi, S., Ishihara, T., Mima, S., Suzuki, K., Ogawa, S. and Mizushima, T.: Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells. Mol. Pharmacol., 71: 860-870 (2007).
14. Tomisato, W., Tsutsumi, S., Hoshino, T., Hwang, H. J., Mio, M., Tsuchiya, T. and Mizushima, T.: Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem. Pharmacol., 67: 575-585 (2004).
15. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W. and Herschman, H. R.: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J. Biol. Chem., 266: 12866-12872 (1991).
16. Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L. and Simmons, D. L.: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA, 88: 2692-2696 (1991).
17. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M. and Geis, G. S.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284: 1247-1255 (2000).
18. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos, V. R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K. and Schnitzer, T. J.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343: 1520-1528 (2000).
19. Mukherjee, D., Nissen, S. E. and Topol, E. J.: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286: 954-959 (2001).
20. Yamakawa, N., Suemasu, S., Kimoto, A., Arai, Y., Ishihara, T., Yokomizo, K., Okamoto, Y., Otsuka, M., Tanaka, K. and Mizushima, T.: Low direct cytotoxicity of loxoprofen on gastric mucosal cells. Biol. Pharm. Bull., 33: 398-403 (2010).
21. Misaka, E., Yamaguchi, T., Iizuka, Y., Kamoshida, K., Kojima, T., Kobayashi, K., Endo, Y., Misawa, Y., Lobayashi, S. and Tanaka, K.: Anti-inflammatory, Analgesic and Antipyretic Activities of Sodium 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl] Propionate Dihydrate (CS-600). Pharmacometrics, 21: 753-771 (1981).
22. Kawano, S., Tsuji, S., Hayashi, N., Takei, Y., Nagano, K., Fusamoto, H. and Kamada, T.: Effects of loxoprofen sodium, a newly synthesized non-steroidal anti-inflammatory drug, and indomethacin on gastric mucosal haemodynamics in the human. J. Gastroenterol. Hepatol., 10: 81-85 (1995).
23. Sugimoto, M., Kojima, T., Asami, M., Iizuka, Y. and Matsuda, K.: Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug. Biochem. Pharmacol., 42: 2363-2368 (1991).
24. Ohara, H., Miyabe, Y., Deyashiki, Y., Matsuura, K. and Hara, A.: Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol., 50: 221-227 (1995).
25. Yamakawa, N., Suemasu, S., Matoyama, M., Tanaka, K.-i., Katsu, T., Miyata, K., Okamoto, Y., Otsuka, M. and Mizushima, T.: Synthesis and biological evaluation of loxoprofen derivatives. Bioorg. Med. Chem., 19: 3299-3311 (2011).
26. Yamakawa, N., Suemasu, S., Matoyama, M., Kimoto, A., Takeda, M., Tanaka, K., Ishihara, T., Katsu, T., Okamoto, Y., Otsuka, M. and Mizushima, T.: Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities. J. Med. Chem., 53: 7879-7882 (2010).
27. Koo, T. S., Kim, D. H., Ahn, S. H., Kim, K. P., Kim, I. W., Seo, S. Y., Suh, Y. G., Kim, D. D., Shim, C. K. and Chung, S. J.: Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: evidence for extrahepatic metabolism. J. Pharm. Sci., 94: 2187-2197 (2005).
28. Suemasu, S., Tanaka, K., Namba, T., Ishihara, T., Katsu, T., Fujimoto, M., Adachi, H., Sobue, G., Takeuchi, K., Nakai, A. and Mizushima, T.: A role for HSP70 in protecting against indomethacin-induced gastric lesions. J. Biol. Chem., 284: 19705-19715 (2009).
29. Choo, K. S., Kim, I. W., Jung, J. K., Suh, Y. G., Chung, S. J., Lee, M. H. and Shim, C. K.: Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method. J. Pharm. Biomed. Anal., 25: 639-650 (2001).
30. Naganuma, H., Mochizuki, Y. and Kawahara, Y.: Study of pharmaco-kinetics following oral administration of loxprofen sodium (CS-600) in humans. J. Clin. Ther. Med., 2: 1219-1237 (1986).
31. Pawlowski, J. E., Huizinga, M. and Penning, T. M.: Cloning and sequencing of the cDNA for rat liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase. J. Biol. Chem., 266: 8820-8825 (1991).
32. Deyashiki, Y., Ogasawara, A., Nakayama, T., Nakanishi, M., Miyabe, Y., Sato, K. and Hara, A.: Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem. J., 299(Pt 2): 545-552 (1994).
33. Tanaka, Y.: Stereoselective metabolism studies on loxoprofen, a 2-arylpropionic acid nonsteroidal anti-inflammatory drug, and its role for the development as a prodrug. Drug Metab. Pharmacokinet., 8: 521-536 (1993).
34. Koo, T. S., Kim, D. H., Ahn, S. H., Kim, K. P., Kim, I. W., Seo, S. Y., Suh, Y. G., Kim, D. D., Shim, C. K. and Chung, S. J.: Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: evidence for extrahepatic metabolism. J. Pharm. Sci., 94: 2187-2197 (2005).